designed to fulfill your health evidence needs
Target RWE is redefining and revolutionizing the generation and delivery of real-world evidence. Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE’s proven real-world data (RWD) solutions are utilized throughout the drug development and commercialization spectrum. With high-quality and comprehensive fit-for-use datasets captured across a broad range of chronic illnesses, Target RWE is well-positioned to support pharmaceutical, industry, life sciences and healthcare partners with their RWE initiatives and programs.
Target RWE designs custom datasets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE regulatory-grade data has been leveraged to support new drug development and label expansion opportunities, address regulatory demands, assess decision-making processes for research and development strategies such sales, marketing and pricing as well as fulfill post-marketing drug safety requirements/commitments in the United States and Europe.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases.
Target RWE works in partnership with numerous industry leaders, regulatory agencies, and key disease stakeholders to support our various healthcare evidence databases. In 2017, Target RWE signed a Cooperative Research and Development Agreement (CRADA) with the FDA which supports the efforts behind the 21st Century Cures Act to enhance the ability to modernize clinical trial designs.